News - bapineuzumab, Pfizer

Filter

Current filters:

bapineuzumabPfizer

Popular Filters

Pfizer and Janssen's bapineuzumab fails to meet one Ph III study endpoints for Alzheimer's

24-07-2012

US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that the co-primary clinical endpoints, change…

bapineuzumabJanssenJohnson & JohnsonNeurologicalPfizerPharmaceuticalResearch

Intellect Neurosciences appeals European patent decision

15-12-2011

US neuro drug discovery firm Intellect Neurosciences (OTCBB: ILNS) says that it has filed an appeal regarding…

bapineuzumabBiotechnologyElanIntellect NeuroscienceLegalNeurologicalPatentsPfizerPharmaceutical

Alzheimer’s drug market to triple to $14.3 billion by 2020, says DR

09-10-2011

The Alzheimer’s disease drug market will nearly triple over the next 10 years, increasing from $5.4…

bapineuzumabEli LillyGlobalJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceuticalsolanezumab

Back to top